SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 590
Posts 90,186
Boards Moderated 28
Alias Born 09/05/02
160x600 placeholder
U.S. Stocks End November With Whimper, Post Modest Monthly Gains
Retail in the spotlight after weekend of holiday shopping U.S. stocks closed slightly lower on Monday, but the main indexes held on to...
Top Equities Stories Of The Day
BHP Shares Plunge as Brazil Files Suit Against Dam Owners -- Update
Correction to Barron's Friday Blog Item on Pfizer-Allergan
Black Friday Shopping With Thinner Crowds
Target Website Has Problems Amid Heavy Traffic
GT Advanced Pursues $80 Million Loan to Exit Bankruptcy
Gates Launches Energy-Innovation Fund
Indian Railways Signs Deals With Alstom, GE for 1,800 Locomotives
BofA Executive Leaves Firm
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19308 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist